WO2018056824A8 - Manipulation of immune activity by modulation of expression - stub1 - Google Patents

Manipulation of immune activity by modulation of expression - stub1 Download PDF

Info

Publication number
WO2018056824A8
WO2018056824A8 PCT/NL2017/050639 NL2017050639W WO2018056824A8 WO 2018056824 A8 WO2018056824 A8 WO 2018056824A8 NL 2017050639 W NL2017050639 W NL 2017050639W WO 2018056824 A8 WO2018056824 A8 WO 2018056824A8
Authority
WO
WIPO (PCT)
Prior art keywords
stub1
expression
immune activity
manipulation
modulation
Prior art date
Application number
PCT/NL2017/050639
Other languages
French (fr)
Other versions
WO2018056824A1 (en
Inventor
Antonius Nicolaas Maria Schumacher
Thijn Reinout BRUMMELKAMP
Chong SUN
Lucas Tilmann JAE
Riccardo Ernesto MEZZADRA
Original Assignee
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis filed Critical Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Publication of WO2018056824A1 publication Critical patent/WO2018056824A1/en
Publication of WO2018056824A8 publication Critical patent/WO2018056824A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of immunity, immune activity and more particularly to the field of "immune check points" including the PD-1/PD-L1 axis, and conditions or diseases involving PD-1/PD-L1 axis signaling. Provided are modulators of immune activity, which modulators influence the activity and/or expression of STUB1.
PCT/NL2017/050639 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression - stub1 WO2018056824A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL2017523 2016-09-23
NL2017523 2016-09-23
NL2019271 2017-07-18
NL2019271 2017-07-18
NL2019281 2017-07-19
NL2019281 2017-07-19

Publications (2)

Publication Number Publication Date
WO2018056824A1 WO2018056824A1 (en) 2018-03-29
WO2018056824A8 true WO2018056824A8 (en) 2018-06-28

Family

ID=60138904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/NL2017/050640 WO2018056825A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression
PCT/NL2017/050639 WO2018056824A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression - stub1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/NL2017/050640 WO2018056825A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression

Country Status (2)

Country Link
EP (1) EP3516390A1 (en)
WO (2) WO2018056825A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201805963D0 (en) * 2018-04-11 2018-05-23 Avacta Life Sciences Ltd PD-L1 Binding Affirmers and Uses Related Thereto
WO2019237388A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Grna sequence for knocking out human btdc gene and application thereof
CN114380907B (en) * 2020-10-16 2024-06-18 中国科学院上海药物研究所 Nanometer antibody targeting CMTM6, and preparation method and application thereof
CN112195224A (en) * 2020-10-23 2021-01-08 漯河医学高等专科学校 Application of gene combined detection reagent in immunotherapy of lung cancer patients
CN116832177A (en) * 2022-03-25 2023-10-03 中国科学院上海药物研究所 Preparation and anti-tumor application of gene therapy vector for interfering expression of chemokine-like factor superfamily member 6 (CMTM 6)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
AU2003264211A1 (en) 2002-09-06 2004-03-29 Mount Sinai Hospital Methods for assaying protein-protein interactions
US7659077B2 (en) * 2003-03-17 2010-02-09 Riikka Lund Methods utilizing target genes related to immune-mediated diseases
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
US20090022731A1 (en) * 2006-08-25 2009-01-22 Wyeth Arthritis-associated B cell gene expression
CN101148472A (en) * 2006-09-13 2008-03-26 北京大学 Tumour inhibitory gene or protein and application thereof
CN101161283B (en) * 2006-10-10 2012-07-11 北京大学 New use of CMTM1-v17 and its antagon
CN101550185B (en) * 2008-04-03 2013-10-30 北京大学 Tumor-related gene or protein and application thereof
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
JP2012517813A (en) 2009-02-16 2012-08-09 エピセンター テクノロジーズ コーポレイション Template-independent ligation of single-stranded DNA
US20120252028A1 (en) * 2009-08-14 2012-10-04 Michael Shtulman Target genes for cancer therapy
CN102309757B (en) * 2010-07-09 2014-09-17 中国科学院上海巴斯德研究所 Novel regulatory factor of FOXP3 and regulatory T cells, and use thereof
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
JP2016525873A (en) * 2013-02-27 2016-09-01 ザ・ブロード・インスティテュート・インコーポレイテッド T cell balance gene expression, composition and method of use thereof
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
CN104225575B (en) * 2013-06-07 2019-08-02 北京大学人民医院 A kind of tumor suppressor gene or albumen and its application
CN105879053A (en) * 2014-09-26 2016-08-24 北京大学 Use of CMTM1-V5 gene and its encoded protein

Also Published As

Publication number Publication date
EP3516390A1 (en) 2019-07-31
WO2018056825A8 (en) 2019-05-31
WO2018056824A1 (en) 2018-03-29
WO2018056825A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
WO2018056824A8 (en) Manipulation of immune activity by modulation of expression - stub1
CL2019000325A1 (en) Pharmaceutical composition comprising a compound derived from substituted polycyclic pyridone or its salt, which has cap-dependent endonuclease inhibitory activity; crystal; and pharmaceutical composition comprising said crystal.
MX2019003735A (en) Dilutable formulations of cannabinoids and processes for their preparation.
MX2018011139A (en) Acrylic acid, and methods of producing thereof.
PH12018502329A1 (en) Modulators of the integrated stress pathway
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2018124766A3 (en) Chimeric antigen receptor and natural killer cells expressing same
AU2017261336A1 (en) Modulators of the integrated stress pathway
PH12017501456A1 (en) Therapeutic cyclic compounds as immunomodulators
WO2015191951A3 (en) Modulation of complement activity
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
BR112019000692A2 (en) Somatostatin modulators and uses of these
EA201691978A1 (en) CONNECTIONS AS ROR GAMMA MODULATORS
WO2015142001A3 (en) Compound having cardiotonic activity and pharmaceutical composition for preventing or treating heart failure, containing same
MX2023004969A (en) METHODS FOR TREATING AND PREVENTING<i> C. DIFFICILE </i>INFECTION.
EP4218790A8 (en) Modulators of complement activity
MX2016003135A (en) Pyridazinone compounds and uses thereof.
WO2017066712A3 (en) Modulators of telomere disease
WO2017066796A3 (en) Modulators of telomere disease
MX2017002768A (en) Antiviral agents and uses thereof.
WO2015144977A8 (en) Trpa1 modulators
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
WO2017106683A3 (en) Concatemeric rna molecules, compositions, and methods and uses thereof
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17787047

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17787047

Country of ref document: EP

Kind code of ref document: A1